Eli Lilly and Company / LLY

Equity | Generated Nov 12, 2026 11:31 PM EST

Current price	Daily move	Bid / Ask	Previous close
$1,434.43	-2.86 -0.20%	$1,431.32/$1,441.10	$1,437.29

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Nov 12, 2026 11:31 PM EST**

JW Intelligence Report

Complete | 3 of 3 sections | Nov 12, 2026 6:50 PM EST

JW Rank	Rank label	Confidence	IV percentile
68.9 / 100	Constructive	high	23 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,415.00	$1,490.00	$1,368.00	49 / 100

Options stance	**bullish**
Tail-risk safety	**45 / 100**
JW Rank data coverage / as of	**100.0% | Nov 12, 2026 6:50 PM EST**

Key insight

Lilly's China Approval Boosts Sentiment, Options Reflect Optimism

Market read

The market is bullish on Lilly (LLY) following the approval of its oral GLP-1 weight-loss drug in China. This news, coupled with positive clinical trial data and a raised revenue guidance, has pushed the stock price higher and increased option buying activity. While some analysts remain cautious about valuation concerns and potential regulatory risks, the overall sentiment is optimistic.

Strategy context

The bullish sentiment is reflected in the option chain, with call options showing higher implied volatility and a slight skew towards calls. This suggests that traders are expecting further upside potential for LLY.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Nov 12, 2026 2:24 PM EST**

Short-term scenario

Tactical long only on a pullback; do not chase strength near 52-week highs. 1–3 week setup is momentum-supported but stretched (RSI near 70) after the China headline. This is analysis, not advice. Uncertainty is high: the catalyst may already be partly priced in, and a failed hold of nearby support could unwind the recent pop quickly.

Three-month outlook

Base case is modestly constructive if GLP-1 execution continues: Mounjaro and Zepbound still drive the majority of growth, oral Foundayo expands the franchise, and China approval widens the addressable market, supported by raised 2026 guidance. Offsetting that, the stock already discounts a premium multiple versus typical pharma peers, sits near highs, and faces competition, pricing/policy risk, and safety headlines. A reasonable three-month range is continued grind higher if growth stays above expectations, or a 8–15% pullback if the multiple compresses. Uncertainty is material: China launch economics, Medicare negotiation exposure, competitive oral GLP-1 timelines, and whether revenue growth can stay near recent rates are all unresolved. Levels and outcomes are not forecasts.

Market sentiment

Recent X discussion is mixed-to-cautiously positive, not uniformly euphoric. Some investors are long-term bullish on the broader pipeline beyond Mounjaro and Zepbound, with one pharmacist-investor citing a possible path toward $2,000 over a long horizon while noting drug and stock risk. Traders treated the China oral approval as a fresh catalyst and noted relative strength, with short-term long setups referenced above roughly $1,364–$1,400. Counterpoints include explicit “don’t buy” commentary on valuation and scattered promotional noise. Sample size is limited, so social sentiment is an incomplete signal. Uncertainty: X volume and quality on this catalyst appear modest and may not represent institutional positioning.

Supporting evidence


LLY shares jumped as much as 3% on the news of China's approval of Foundayo, an oral GLP-1 weight-loss pill. | The company also reported positive clinical trial data for Taltz plus Zepbound in psoriatic arthritis with obesity and for Foundayo in sleep apnea. | Lilly raised its 2026 revenue guidance to $91–$92 billion, exceeding analyst expectations. | Analyst consensus is generally Buy, with some targets reaching $1,500–$1,700.

Risk watch

Valuation concerns remain as LLY trades at a premium multiple compared to typical pharma peers. | Potential Medicare drug-price negotiations could impact future profitability. | An FDA note on a possible vision-loss risk for GLP-1 drugs adds uncertainty.

Enhanced price structure

45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	Above MVWAP	Above 200D trend	medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | neutral | MACD accelerating**
Trend signal	**STRONG BULL**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**67.12 / 67.96 / 66.65**
RSI velocity	**0.04**
MACD line / signal / histogram	**56.87 / - / 52.85**
MACD acceleration	**0.92**
Stochastic K / D	**88.32 / 82.56**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Above institutional MVWAP | Accumulation bias**
Institutional flow	**9.66**
20-day MVWAP	**$1,365.23**
Price vs 20-day MVWAP	**+5.07%**
Daily reference VWAP	**$1,438.19**
Price vs daily reference	**-0.26%**
Volume	**1.60M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**11.17**
20-day / 200-day SMA	**$1,346.92 / $1,107.23**
Bollinger range	**$1,206.41 - $1,487.44**
Bollinger position	**0.786**

Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
21 / 100	20 / 100	98.09	149.09

Market regime	**COMPRESSION RISK**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**backwardation**
Term slope	**-5.36 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 12, 2026 2:55 PM EST**
Options data quality	**Coverage 100.0%**

Option term structure

ATM implied-volatility curve by days to expiration



Downward-sloping ATM volatility term structure


EXPIRATION	DTE	ATM IV	STATE
2026-11-13	1	34.8%	-
2026-11-20	8	31.1%	-
2026-11-27	15	29.4%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference


Short $1,415.00 | Long $1,412.50 | Width $2.50 | Net credit $0.58



Max profit $58.00 | Max loss -$192.00 | Break-even $1,414.42 | Per contract at expiry

Bear Call Spread reference

Short $1,450.00 | Long $1,455.00 | Width $5.00 | Net credit $1.23



Max profit $123.00 | Max loss -$377.00 | Break-even $1,451.23 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**elevated**
Event IV premium	**3.73**
VIX	**18.65**
VVIX	**98.09**
SKEW index	**149.09**
Observation confidence	**high**
Option quote quality	**reliable**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts observed	**118**
Contracts with quotes	**118**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The market is bullish on Lilly (LLY) following the approval of its oral GLP-1 weight-loss drug in China. This news, coupled with positive clinical trial data and a raised revenue guidance, has pushed the stock price higher and increased option buying activity. While some analysts remain cautious about valuation concerns and potential regulatory risks, the overall sentiment is optimistic.

Options context

Lilly's China Approval Boosts Sentiment, Options Reflect Optimism

Wheel context

The bullish sentiment is reflected in the option chain, with call options showing higher implied volatility and a slight skew towards calls. This suggests that traders are expecting further upside potential for LLY.

Observed evidence

LLY shares jumped as much as 3% on the news of China's approval of Foundayo, an oral GLP-1 weight-loss pill. | The company also reported positive clinical trial data for Taltz plus Zepbound in psoriatic arthritis with obesity and for Foundayo in sleep apnea. | Lilly raised its 2026 revenue guidance to $91–$92 billion, exceeding analyst expectations. | Analyst consensus is generally Buy, with some targets reaching $1,500–$1,700.

Principal risks to monitor

Valuation concerns remain as LLY trades at a premium multiple compared to typical pharma peers. | Potential Medicare drug-price negotiations could impact future profitability. | An FDA note on a possible vision-loss risk for GLP-1 drugs adds uncertainty.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
$1.35T	**48.86**
ROE	Revenue growth
83.7%	**31.7%**
EPS growth	Operating margin
49.3%	**40.3%**
Net profit margin	Gross margin
31.9%	**-**
Free cash flow CAGR	Debt / equity
5.9%	**1.60**
Dividend yield	Beta
0.8%	**0.37**

52-week range

$850.51 - $1,453.00

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Company	**NYSE**
Industry	Country
Pharmaceuticals	**US**
Currency	IPO date
USD	**1970-07-09**
Shares outstanding	52-week return
940.75M	**48.2%**
Book value per share	Revenue per share
$42.79	**$96.78**

Website	lilly.com

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Nov 4, 2026 3:45 PM EST

Covered Call | 2026-11-06

At signal $1,422.74 | Current $1,434.43

SHORT **Option $1,425.00 B $14.30 / A $14.95**

Conservative | CR $14.63

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$45.42**
ATR as % of price	**3.2%**
Volatility environment	**medium**
Current IV	**31.9%**
IV rank	**23 / 100**
IV percentile	**23 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Nov 12, 2026 6:31 PM EST**

Technical health and risk radar

Derived indicator health and event context

Overall health	**78 / 100**
Trend health	**92 / 100**
Momentum health	**77 / 100**
Volatility health	**62 / 100**
Structure health	**71 / 100**
Earnings risk / date	**unknown | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,346.92 / $1,235.40 / $1,107.23**
EMA (9 / 21)	**$1,401.04 / $1,347.89**
Bollinger upper / middle / lower	**$1,487.44 / $1,346.92 / $1,206.41**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.786**
True high / low	**$1,460.00 / $1,427.28**
5-day true high / low	**$1,460.00 / $1,333.22**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	11.167	**-**
SMA50	5.467	**-**
MVWAP20	9.665	**-**
MACD	0.922	**-**
RSI	0.038	**-**
Volume	-125448.000	**-**
ATR	-1.079	**-**
T1	-	**57.32 / 1354.21 / 1440.47 / 1414.37**
T2	-	**56.04 / 1344.02 / 1438.88 / 1400.00**
T3	-	**54.10 / 1336.23 / 1419.67 / 1354.00**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,434.36**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 12, 2026 2:55 PM EST**
Options data coverage	**100.0%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FALLING**
Front expiration / DTE	**2026-11-13 | 1 DTE**
Front at-the-money IV	**34.8%**
25-delta skew	**3.39**
Put / Call 25-delta	**$1,415.00 Delta -0.261 / $1,450.00 Delta 0.261**
Median option bid/ask spread	**12.0%**
Bid/ask spread	**-**
Contracts observed / quoted	**118 / 118**

Price context

Last Price: 1,434.36 | Bid: 1,434.04 | Ask: 1,434.67 | Previous Close: 1,437.29 | Change: -2.93 | Daily change: -0.20% | Update Time: 2026-11-12T14:55:39.318807-05:00 | Latest History Date: 2026-11-12 | Latest History Price: 1,434.36

Historical context

Trading-day sample: 60 sessions | First Date: 2026-08-20 | Latest Date: 2026-11-12 | Latest Price: 1,434.36 | Max Drawdown 60d Percent: -11.13%

Fundamental context

Current Iv Percent: 31.59% | Iv Rank: 21.26 | Iv Percentile: 20.32 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-11-12

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Nov 12, 2026 11:31 PM EST. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**